NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading PDEX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity with a focus on revenue and earnings growth. The current thesis state is intact, supported by recent financial performance, but there are underlying risks that could impact future results.
PDEX is currently valued as cheap compared to its peers, reflecting a low expectations gap. The market seems to have priced in some fragility due to weak execution quality, but not to the extent of a major downturn.
Fundamentals are likely to show continued revenue growth, as indicated by recent results. However, operating income growth is limited, and there is a low probability of missing earnings expectations, though the risks are higher due to the company's smaller size and erratic earnings history.
The thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX. Positive earnings and guidance from these companies could support PDEX, while any negative shifts could pose risks to its growth trajectory.
Over the next 1 to 3 years, PDEX's performance will depend on both its execution and broader sector trends. Not investment advice.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. The recent financial performance remains strong, and the reasons to own it still hold. There are no new threats or supports that would alter the current assessment.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This report will provide insights into revenue and earnings performance. It is a key indicator of business health.
Confirms one read:Earnings report shows strong revenue and profit growth.
Confirms the other:Earnings report shows weak revenue and profit growth.
Why it matters: If growth is over 15%, it shows strong demand. This is true for the biggest customer.
Confirms:Q3 revenue growth exceeds 15% year over year, reaching above $19.9 million.
Disproves:Q3 revenue growth falls below 15% year over year.
Why it matters: If the health care sector's revenue growth speeds up, it could benefit Pro-Dex. This may improve investor sentiment.
Confirms:Health care sector revenue growth is speeding up again. It is moving toward 10% or more.
Disproves:Health care sector revenue growth slows below 5%.
Why it matters: Growing revenue shows the company is meeting its financial goals.
Confirms:Q4 revenue exceeds $20M, showing continued growth from previous quarters.
Disproves:Q4 revenue falls below $19.95M, indicating a slowdown in growth.
Why it matters: Confirming this EPS guidance shows Pro-Dex is on track to meet its profit goals. It reflects financial health.
Confirms:EPS reported at or above $3.27 for fiscal year 2026.
Disproves:EPS reported below $3.27 for fiscal year 2026.
Why it matters: If peers like Lilly or AbbVie show strong earnings, it may lift Pro-Dex's profile. It shows how the market views the sector.
Confirms one read:Lilly or AbbVie reports earnings growth above 15% year over year.
Confirms the other:Lilly or AbbVie reports earnings decline of 5% or more year over year.
Why it matters: News about this deal shows how Pro-Dex is growing. It affects future growth.
Confirms one read:Look for news on when the deal is done or major steps forward.
Confirms the other:No updates or delays in the acquisition process.
